Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
Status:
Recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab
soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate
receptor alpha (FRα).